<http://schema.org/description>
"Repros Therapeutics provided top-line results from the ZA-301 study on its late-stage candidate, Androxal, which is being evaluated for the treatment of secondary hypogonadism"^^<http://www.w3.org/2001/XMLSchema#string>
<https://www.zacks.com/stock/news/96334/positive-data-on-repros-androxal>